Ferretti Lauren, Mellis Rhiannon, Chitty Lyn S
Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Rd, London, UK.
Great Ormond Street NHS Foundation Trust, Great Ormond Street, London, UK.
Eur J Med Genet. 2019 Aug;62(8):103663. doi: 10.1016/j.ejmg.2019.05.002. Epub 2019 May 11.
Unexpected fetal abnormalities detected through ultrasound scanning in pregnancy may have a monogenic aetiology but are difficult to diagnose. Next generation sequencing now enables us to sequence fetal exomes, providing increased resolution and broader diagnostic capability compared to traditional cytogenetic prenatal tests, improving the yield and accuracy of diagnoses and allowing better counselling for expectant parents. Here we review published studies of exome sequencing (ES) for prenatal diagnosis over the last 5 years and address important questions for its clinical implementation, including clinical utility, which groups benefit most, and practical and ethical challenges for interpreting and reporting results. We observe that fetal ES substantially improves diagnostic yield relative to cytogenetic techniques. However, diagnostic rates vary widely between studies, largely attributable to differences in case selection. Recently several large studies report variations in diagnostic yield between phenotypic groups, with fetuses with multisystem abnormalities most likely to receive a diagnosis from fetal ES. Challenges for prenatal ES include the limitations of ultrasound-based fetal phenotyping, the need for rapid return of results in pregnancy, and technical limitations compared to whole genome sequencing. We also consider ethical issues around potential secondary findings and variants of uncertain significance and the complex counselling needs these present. Prenatal ES is a valuable tool to diagnose fetal abnormalities and, as it is implemented in the clinic, more large-scale research will serve to further delineate its clinical utility, as well as generating new knowledge about fetal phenotypes and informing guidelines for case selection, reporting results and genetic counselling.
孕期超声扫描检测到的意外胎儿异常可能具有单基因病因,但难以诊断。新一代测序技术使我们能够对胎儿外显子组进行测序,与传统的细胞遗传学产前检测相比,其分辨率更高,诊断能力更强,提高了诊断的阳性率和准确性,并能为准父母提供更好的咨询服务。在此,我们回顾了过去5年发表的关于外显子组测序(ES)用于产前诊断的研究,并探讨了其临床应用中的重要问题,包括临床实用性、哪些群体受益最大,以及解读和报告结果时面临的实际和伦理挑战。我们观察到,相对于细胞遗传学技术,胎儿ES显著提高了诊断阳性率。然而,不同研究之间的诊断率差异很大,这在很大程度上归因于病例选择的差异。最近有几项大型研究报告了不同表型组之间诊断阳性率的差异,多系统异常的胎儿最有可能通过胎儿ES获得诊断。产前ES面临的挑战包括基于超声的胎儿表型分析的局限性、孕期需要快速返回结果,以及与全基因组测序相比的技术局限性。我们还考虑了围绕潜在次要发现和意义不确定的变异的伦理问题,以及这些问题带来的复杂咨询需求。产前ES是诊断胎儿异常的一项有价值的工具,随着它在临床中的应用,更多的大规模研究将有助于进一步阐明其临床实用性,同时也能产生关于胎儿表型的新知识,并为病例选择、报告结果和遗传咨询提供指导。